ViGenCell

ViGenCell Retained Earnings

The Retained Earnings of ViGenCell (308080.KQ) as of Oct 19, 2026 is -118.28 B KRW. In the previous year, Retained Earnings was -102.32 B KRW — a change of 15.59% (lower).

Retained Earnings

-118.28 BKRW

YoY

15.59%

Last updated:

Retained Earnings of ViGenCell is 2025 -118.28 B KRW. Retained Earnings of ViGenCell was 2024 -102.32 B KRW. It decreases by 15.59% lower compared to the previous year.

The ViGenCell Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2019
-30.54 B KRW
Jan 1, 2020
-41.10 B KRW
Jan 1, 2021
-52.40 B KRW
Jan 1, 2022
-69.82 B KRW
Jan 1, 2023
-88.59 B KRW
Jan 1, 2024
-102.32 B KRW
Jan 1, 2025
-118.28 B KRW
The ViGenCell Retained Earnings history
YEARRetained EarningsYoY
-118.28 BKRW+15.59%
-102.32 BKRW+15.50%
-88.59 BKRW+26.89%
-69.82 BKRW+33.25%
-52.40 BKRW+27.47%
-41.10 BKRW+34.60%
-30.54 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViGenCell Stock analysis

What does ViGenCell do? ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea. ViGenCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViGenCell stock

Retained Earnings of ViGenCell is -118.28 B KRW in 2025.

Retained Earnings of ViGenCell changed from -102.32 B KRW to -118.28 B KRW, representing a 15.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings ViGenCell since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's ViGenCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViGenCell

All Key Metrics — ViGenCell